U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07431112) titled 'A Phase 1 Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)' on Feb. 19.
Brief Summary: This is a Phase 1, open-label, single ascending dose (SAD) and multiple dose (MD) study of AIR-001 in participants with alpha-1 antitrypsin deficiency (AATD) due to PiZZ genotype.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Alpha 1 Antitrypsin Deficiency
Intervention:
DRUG: AIR-001 SAD dose level 1
AIR-001 dose level 1 - single subcutaneous (sc) injection
DRUG: AIR-001 SAD dose level 2
AIR-001 dose level 2 - single subcutaneous (sc) injection
DRUG: AIR-001 SAD dose level 3
AIR-001 dose level 3...